Latest News and Press Releases

ANN ARBOR, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...

- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...

ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...

Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...

ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...

ANN ARBOR, Mich., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of...

Presentation and Webcast on Wednesday, November 16, 2016 at 3:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical...

ANN ARBOR, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...

Presentation and Webcast on Tuesday, November 8, 2016 at 3:00 p.m. Pacific Time/6:00 p.m. Eastern Time ANN ARBOR, Mich., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....

ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...